Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
Status:
Completed
Trial end date:
2003-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the protocol, is to evaluate if lanreotide Autogel 120 mg is effective in the
control of Growth Hormone (GH) secretion in patients with active acromegaly.